RDIF, Stelis Biopharma partner to supply 200 mn doses of Sputnik V vaccine

Stelis' pact with the Russian Direct Investment Fund (RDIF) follows similar deals struck by Indian pharmaceutical firms Gland Pharma and Hetero to make millions of doses of the vaccine, which has proven to be 91.6% effective against COVID-19.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news